ClinicalTrials.gg
CompletedNCT02145104Updated Jun 13, 2018

Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

A Phase 3 interventional study of valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg in Hypertension, sponsored by IlDong Pharmaceutical Co Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
58th of 139
286 · median 198
Started
2014
the only one that year
Phase 3
53 of 140
none open now
Registered
124th of 140
by date
Lead sponsor
2 of 140
IlDong Pharmaceutical Co Ltd

Among the 140 studies testing valsartan in Hypertension, this one is the 58th largest by enrollment of the 139 interventional ones that give a count, is the only one that started in 2014, is one of 53 in phase 3, and was the 124th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is to evaluate of efficacy and safety of cilinidipine plus valsartan and valsartan alone in patients with essential hypertension inadequately controlled on valsartan monotherapy

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • essential hypertension patients whose blood pressure is not controlled before the study (sDBP≥90mmHg for drug-treated patients, sDBP≥95mmHg for drug-naive patients)

Exclusion criteria

Exclusion Criteria:

  • sSBP≥80mmHg after 4weeks of valsartan 160mg treatment
  • has a history of to dihydropyridines or angiotensin II receptor blockers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Arm A

    cilinidpine 10mg + valsartan 160mg

    Drug: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

  • Experimental
    Arm B

    cilnidipine 5mg + valsartan 160mg

    Drug: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

  • Active comparator
    Arm C

    valsartan 160mg

    Drug: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

06

What researchers measure

Primary outcomes

  1. change from baseline in mean sDBP

    Time frame: 8 weeks

Secondary outcomes

  1. change from baseline in mean sDBP

    Time frame: 4 weeks

  2. change from baseline in mean sSBP

    Time frame: 4, 8 weeks

07

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam-si, Kyung-gi, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jun 2016, 23 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 23 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2014
First posted
May 22, 2014
StartActual
Jun 17, 2014
Primary completionActual
Jun 7, 2016
CompletionActual
Sep 29, 2016
Last update
Jun 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02145104
Responsible party
Sponsor
First posted
May 22, 2014
Start date
Jun 17, 2014
Primary completion
Jun 7, 2016
Completion
Sep 29, 2016
Last update
Jun 13, 2018

Study contacts

Dong Ju Choi, M.D., Ph.D.
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion